Dogwood Therapeutics Inc (DWTX)
Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on therapies for pain and fatigue-related disorders. The company’s pipeline includes IMC-1, a combination of famciclovir and celecoxib that has completed a Phase 2b clinical trial for fibromyalgia; Halneuron, which is being studied in Phase 2b trials for chemotherapy-induced neuropathic pain and cancer pain and is also in preclinical development for acute surgical pain; IMC-2, a combination of valacyclovir and celecoxib designed to suppress herpesvirus activation; and Serpin Peptide 16, which is in early Phase 1 development for neuropathy associated with neurotoxic chemotherapeutic agents. Formerly known as Virios Therapeutics, Inc., the company adopted its current name in October 2024. Dogwood Therapeutics was founded in 2012 and is based in Alpharetta, Georgia.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DWTX
|
$1.88
|
37.3% Upside
|
Undervalued
|
$14
|
923.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-1.6x
|
0.6x
|
—
|
46.409 M
|
32.922 M
|
0.3%
|
15.8%
|
-1.0
|
—
|
54.8%
|
